ISRCTN14668776 https://doi.org/10.1186/ISRCTN14668776

Deferred registration - Quotient Sciences code: QSC303694

Submission date 04/06/2026	**Recruitment status** Not yet recruiting	[X] Prospectively registered [ ] Protocol [ ] Statistical analysis plan [ ] Results [ ] Individual participant data [X] Record updated in last year
Registration date 24/06/2026	**Overall study status** Deferred	
Last Edited 24/06/2026	**Condition category** Other	

Plain English summary of protocol
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Contact information

Type(s)
Principal investigator

Contact name
Dr David Everton

Contact details
Mere Way, Ruddington Fields
Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)1159749000
recruitment@weneedyou.co.uk

Type(s)
Scientific, Public

Contact name
None Clinical Operations

Contact details
Avenue de la Gare 39
Lausanne
Switzerland
1003

+41 (0)21 711 3970
info@oculis.com

Additional identifiers

Integrated Research Application System (IRAS)
1013199

CRO Study Code
QSC303694

Study information

Scientific Title
CTIMP - Quotient Sciences code: QSC303694 [The full scientific title will be added on or before the deferral expiry date]

Study objectives
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Ethics approval required
Ethics approval required

Ethics approval(s)
Approved 08/06/2026, London – Harrow Research Ethics Committee (Health Research Authority 2 Redman Place Stratford, London, E20 1JQ, United Kingdom; +44 (0)2071048357; harrow.rec@hra.nhs.uk), ref: 26/LO/0330

Primary study design
Interventional

Allocation
N/A: single arm study

Masking
Open (masking not used)

Control
Uncontrolled

Assignment
Single

Purpose
Phase I study in healthy volunteers

Study type(s)

Health condition(s) or problem(s) studied

Healthy volunteers

Interventions
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Intervention Type
Drug

Phase
Phase I

Drug/device/biological/vaccine name(s)
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Primary outcome(s)
1. [Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]. This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Key secondary outcome(s)

Completion date
12/08/2026

Eligibility

Key inclusion criteria
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Healthy volunteers allowed
Yes

Age group
Mixed

Lower age limit
18 Years

Upper age limit
65 Years

Sex
Male

Total final enrolment
0

Key exclusion criteria
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Date of first enrolment
06/07/2026

Date of final enrolment
12/08/2026

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Quotient Sciences Limited
Mere Way, Ruddington Fields
Ruddington
Nottingham
England
NG11 6JS

Sponsor information

Organisation
Neurocol Operations Sàrl

Funder(s)

Funder type

Funder Name
Neurocol Operations Sàrl

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available